+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of RAY1225 in adults with obesity. This phase 2 study aims to learn about how well participants tolerate RAY1225 and also explores how it may help with weight loss. The study is expected to last about six months for each participant and is sponsored by Guangdong Raynovent Biotech Co., Ltd. Participants will be randomly assigned to receive either one of two doses of RAY1225 or a placebo. The treatments are given by subcutaneous injection once every two weeks for 24 weeks. There are two groups receiving escalating doses of RAY1225 and two placebo groups, all following the same dosing schedule. During the study, participants will be monitored for changes in body weight and waist circumference from the start of the study to week 26. Researchers will also track the percentage of participants who achieve weight loss of 5%, 10%, or 15%. Assessments will include safety and tolerability evaluations throughout the treatment period. The total participation time for each person is about six months.

Age: 18Years - 70YearsAll GendersPhase 2
1 location
S

Actively Recruiting

Researchers are evaluating Senl-T7 CAR T cells in patients with relapsed or refractory CD7 acute T lymphoblastic leukemia or T lymphoblastic lymphoma. This open, prospective, dose-escalation clinical study aims to assess the safety and effectiveness of Senl-T7 while collecting pharmacokinetic and pharmacodynamic data to better understand its behavior in the body. Participants will receive preconditioning treatment before being infused with the Senl-T7 CAR T cells, which include components targeting CD7 on cancer cells. After infusion, patients will be closely monitored for adverse reactions and treatment response to evaluate safety and remission rates. During the study, patients will undergo regular evaluations, including monitoring for side effects within the first month and assessing remission status at three months post-infusion. Researchers will track adverse events and treatment outcomes to determine the impact of Senl-T7 on the disease. Participation duration can extend up to several months as outcomes are measured over time.

Age: 2Years - 70YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining targeted therapy, immunotherapy, and chemotherapy as a neoadjuvant treatment for patients with locally advanced, resectable head and neck squamous cell carcinoma HNSCC. This phase II, single-arm prospective study focuses on patients aged 18 to 75 with stage III-IVB disease. The goal is to study the major pathological response rate and other important outcomes in this patient group. Participants will receive up to three 3-week cycles of neoadjuvant therapy including nimotuzumab given weekly on days 1, 8, and 15 toripalimab on day 1 and chemotherapy drugs nab-paclitaxel and cisplatin on day 1 of each cycle. About one month after the last neoadjuvant treatment, patients will undergo radical surgery. Postoperative treatments will be chosen based on individual high-risk pathological factors. The study includes regular follow-up to monitor efficacy and safety. During the study, patients will have assessments including pathological evaluations at surgery, imaging according to RECIST 1.1, and safety monitoring using standard criteria. Researchers will also collect data on survival rates, quality of life, and prognostic biomarkers before and after treatment. Participation is expected to last at least two years after enrollment of the last patient, allowing long-term outcome tracking.

Age: 18Years - 75YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a phase III clinical trial to evaluate the protective effects, safety, and immune response of a recombinant respiratory syncytial virus RSV vaccine made with CHO cells. The study involves adults aged 60 years and older, including about 30% aged 70 and above, with a balanced mix of men and women. Participants are randomly assigned to receive either the vaccine or a placebo, and the trial aims to assess the vaccines ability to prevent lower respiratory tract disease caused by RSV. Participants will receive one dose of either the investigational vaccine or a placebo injection on Day 0. The vaccine dose involves mixing an antigen powder with an adjuvant liquid before intramuscular injection into the upper arm. The placebo consists of a sodium chloride solution administered similarly. A subset of 1,200 participants will have their immune response closely studied. The trials evaluation period can last up to 12 months following vaccination. During the study, participants will be monitored for respiratory illnesses, including lower respiratory tract disease and acute respiratory infections, with assessments starting 14 days after vaccination and continuing for up to a year. Safety will be carefully tracked through reports of adverse events within days to a year after vaccination. The study includes scheduled follow-ups to collect data on vaccine effectiveness and immune response. Participation may last up to 12 months from the vaccination date.

Age: 60Years +All GendersPhase 3
7 locations